Impact of the Core Architecture of Dual pH-Responsive Polymer Nanoparticles on Intracellular Delivery of Doxorubicin
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide We report the design of dual pH-responsive multicomponent nanoparticles with tunable core polymer architectures to understand how polymer architecture affects intracellular therapeutic delivery. Star and linear core polymers were synthesized using charge shifting monomers, with anticancer drug doxorubicin (Dox) covalently conjugated via hydrazone linkages. Nanoparticles comprising either a star or linear core were designed by self-assembly with an amphiphilic block copolymer. Despite similar physicochemical properties, nanoparticles with a linear core displayed higher toxicity in MCF-7 cells (IC 50 = 60 ng/mL) compared to that of the star core (IC 50 > 1000 ng/mL), suggesting that polymer architecture influenced drug release behavior.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
Centre for Materials Science, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia
School of Chemistry and Physics, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia
Funding
Australian Research Council · Queensland University of Technology
References (30)
Show source-provided references
1. 10.1021/acsabm.2c0000210.1021/acsabm.2c00002 ↗
2. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
3. 10.1038/nbt.333010.1038/nbt.3330 ↗
4. 10.1016/j.nantod.2022.10151210.1016/j.nantod.2022.101512 ↗
5. 10.1021/acs.chemrev.5b0013510.1021/acs.chemrev.5b00135 ↗
6. 10.1039/C2CS35265F10.1039/C2CS35265F ↗
7. 10.1038/nmat377610.1038/nmat3776 ↗
8. 10.1002/wnan.152710.1002/wnan.1527 ↗
9. 10.1002/adma.20140508410.1002/adma.201405084 ↗
10. 10.1002/marc.20180091710.1002/marc.201800917 ↗
11. 10.1021/acsami.1c1835910.1021/acsami.1c18359 ↗
12. 10.1021/acs.nanolett.0c0446810.1021/acs.nanolett.0c04468 ↗
13. 10.1021/acs.nanolett.2c0018510.1021/acs.nanolett.2c00185 ↗
14. 10.1002/adtp.20190020210.1002/adtp.201900202 ↗
15. 10.1016/j.biomaterials.2017.07.00410.1016/j.biomaterials.2017.07.004 ↗
16. 10.1071/CH1926910.1071/CH19269 ↗
17. 10.1002/mabi.20160024810.1002/mabi.201600248 ↗
18. 10.1021/acsanm.8b0033810.1021/acsanm.8b00338 ↗
19. 10.1071/CH0507210.1071/CH05072 ↗
20. 10.1002/adfm.20190100110.1002/adfm.201901001 ↗
21. 10.1021/acs.chemrev.6b0000810.1021/acs.chemrev.6b00008 ↗
22. 10.1021/acsami.6b0200610.1021/acsami.6b02006 ↗
23. 10.1016/j.progpolymsci.2015.02.00210.1016/j.progpolymsci.2015.02.002 ↗
24. 10.1021/acs.biomac.8b0042510.1021/acs.biomac.8b00425 ↗
25. 10.1021/acsapm.2c0129110.1021/acsapm.2c01291 ↗
26. 10.1002/marc.20170041010.1002/marc.201700410 ↗
27. 10.1039/D0SC00078G10.1039/D0SC00078G ↗
28. 10.1111/j.2042-7158.2012.01567.x10.1111/j.2042-7158.2012.01567.x ↗
29. 10.1021/acs.bioconjchem.8b0073210.1021/acs.bioconjchem.8b00732 ↗
30. 10.1021/la501521910.1021/la5015219 ↗